Navigation Links
Omthera Stockholders Approve Acquisition by AstraZeneca
Date:7/16/2013

PRINCETON, N.J., July 16, 2013 /PRNewswire/ -- The stockholders of Omthera Pharmaceuticals, Inc. (NASDAQ: OMTH) (the "Company") voted today at a special meeting of stockholders to adopt the previously announced merger agreement providing for the acquisition of the Company by an affiliate of AstraZeneca PLC.  The votes cast by the Company's stockholders in favor of the proposal to adopt the merger agreement represented approximately 88.3 percent of the Company's issued and outstanding common stock entitled to vote as of June 13, 2013, the record date for the special meeting.

(Logo: http://photos.prnewswire.com/prnh/20130528/NY21129LOGO-a)

The receipt of the approval of the Company's stockholders of the proposal to adopt the merger agreement satisfies one of the conditions to consummation of the proposed merger.  The consummation of the merger remains subject to certain other closing conditions set forth in the merger agreement.

About Omthera Pharmaceuticals, Inc.

Omthera Pharmaceuticals, Inc. is an emerging specialty pharmaceutical company focused on the development and commercialization of new therapies for dyslipidemia and the treatment of cardiovascular disease. Epanova™, currently the Company's sole product candidate, is a late-stage, novel, omega-3 free fatty acid composition that meaningfully reduces triglycerides, improves other key lipid parameters and is expected to increase patient convenience with 2-gram once-a-day dosing with or without meals. Epanova™ is a coated soft gelatin capsule containing a complex mixture of polyunsaturated free fatty acids derived from fish oils, including multiple long-chain omega-3 and omega-6 fatty acids, with EPA, DHA, and docosapentaenoic acid being the most abundant forms of omega-3 fatty acids. The Company has completed pharmacokinetic and Phase III clinical studies to investigate the safety and efficacy profile of Epanova™. In 2012 the Company reported positive results from its Phase III EVOLVE and ESPRIT trials, both of which were conducted under SPA agreements with the U.S. Food and Drug Administration. Omthera holds worldwide rights to Epanova™ under a license from Chrysalis Pharma AG, a privately held Swiss company that is the owner of the product. For more information, please visit http://www.omthera.com.

Safe Harbor for Forward-Looking Statements

This press release, in particular statements regarding the proposed transaction between an affiliate of AstraZeneca PLC and the Company, the expected timetable for completing the transaction, future financial and operating results, benefits and synergies of the transaction, future opportunities for the combined company and any other statements about AstraZeneca PLC or Company managements' future expectations, beliefs, goals, plans or prospects, includes forward-looking statements that are based on certain beliefs and assumptions and reflect the current expectations of the Company, AstraZeneca PLC and their respective management. Statements that are predictive in nature, that depend on or relate to future events or conditions, or that include words such as "believes," "anticipates," "expects," "continues," "predict," "potential," "contemplates," "may," "will," "likely," "could," "should," "estimates," "intends," "plans" and other similar expressions are forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Forward-looking statements involve known and unknown risks, assumptions and uncertainties that may cause actual results in future periods to differ materially from those projected or contemplated in the forward-looking statements, and you should not place undue reliance on these statements. Some of the factors that could cause actual results to differ materially from current expectations are: the ability to consummate the proposed transaction; any conditions imposed on the parties in connection with the consummation of the proposed transaction; the ability to obtain regulatory approvals of the proposed transaction; the occurrence of any event, change or other circumstances that could give rise to the termination of the agreement relating to the proposed transaction; the Company's ability to maintain relationships with employees and third parties following announcement of the proposed transaction; the ability of the parties to satisfy the conditions to the closing of the proposed transaction; the risk that the proposed transaction may not be completed in the time frame expected by the parties or at all; and the risks that are described from time to time in the Company's reports filed with the SEC, including the Prospectus, in other of the Company's filings with the SEC from time to time, including Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, and on general industry and economic conditions. If the proposed transaction is consummated, our stockholders will cease to have any equity interest in the Company and will have no right to participate in its earnings and future growth. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

NY: 800258-3

Omthera Contact:
Christian Schade
Executive Vice President & Chief Financial Officer
Omthera Pharmaceuticals, Inc.
T: 908-741-4399
E: info@Omthera.com  


'/>"/>
SOURCE Omthera Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Omthera Announces Waiver of Lock-Up Restriction
2. Omthera Pharmaceuticals Announces Record Date and Meeting Date for Special Meeting of Stockholders
3. Omthera Pharmaceuticals, Inc. Stockholders Seeking More Money, Information in Buyout Should Contact Deans & Lyons Law Firm
4. Omthera Pharmaceuticals Announces First Quarter 2013 Financial Results
5. Covington Advises Omthera Pharmaceuticals on Merger with AstraZeneca
6. Omthera Pharmaceuticals, Inc. Announces Closing of Initial Public Offering
7. Omthera Pharmaceuticals, Inc. Announces Pricing of Initial Public Offering
8. Omthera Pharmaceuticals Presents Data From Analysis Of EVOLVE Trial Showing That Epanova Lowers ApoC-III, A Key Predictor of Cardiovascular Risk
9. Omthera Pharmaceuticals Announces Invitation to Attend Presentation of the Complete Data Sets from its Phase 3 EVOLVE and ESPRIT Clinical Studies
10. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
11. Isis Pharmaceuticals to Present a General Corporate Update at its 2013 Annual Meeting of Stockholders and Open House
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... 2017 A new independent study demonstrates ... proven ultraviolet-C (UV-C) disinfection solution of choice for ... Published in the March issue of ... the peer-reviewed study of UV-C disinfection systems detailed ... Hospital and Rochester General Hospital. According to the ...
(Date:3/22/2017)... NEW YORK , March 22, 2017 ... Electrophysiology (EP) market is growing rapidly due to the ... a report published by Allied Market Research, the global ... is expected to reach $8.271 billion by 2022, with ... cardiology and is used to diagnose abnormal heartbeats or ...
(Date:3/22/2017)... ROCKVILLE, Md. , March 22, 2017 ... that should be important to those following the industry.  This ... point-of-care (POC) RSV test, and the POC testing market ... grow. An Alere subsidiary is facing a legal battle ... Meanwhile, Beckman Coulter launched a new chemistry ...
Breaking Medicine Technology:
(Date:3/22/2017)... California (PRWEB) , ... March 22, 2017 , ... Old ... British boxing champ Ashley Theophane as a new Brand Ambassador. Theophane, who trained with ... light welterweight title in 2011. He has racked up an impressive number of wins ...
(Date:3/22/2017)... ... March 22, 2017 , ... ... announced that its digital marketing solutions have enabled Children’s Hospital of The King’s ... months. , Recognizing the value of a digital marketing approach, the 206-bed ...
(Date:3/22/2017)... ... 22, 2017 , ... The Burke Medical Research Institute (BMRI) ... in basic neuroscience at the BMRI labs into new and improved treatments for ... vision, and cognition impaired by stroke, traumatic brain injury, cerebral palsy, and birth ...
(Date:3/22/2017)... , ... March 22, 2017 , ... The Vanderbeck Agency, ... the greater Nassau County region, is embarking on a combined charity effort with the ... , For the last 25 years, the Great Neck Breast Cancer Coalition has worked ...
(Date:3/22/2017)... ... March 22, 2017 , ... Chris Humphrey Insurance Agency, ... and business professionals throughout the coastal plains region, is initiating a charity event to ... , Dillyn was first diagnosed with leukemia on a Friday evening in September 2014. ...
Breaking Medicine News(10 mins):